"Squeezing out the last retail." Absolutely. The narrative around this company is 100% negative for several years. in 2022, it was determined that Vitiligo would finally be worthy of payment. The market is massive, the likelihood of approval high, but the process long. The script writers saw an opportunity to drown this company and their loyal retail following. Despite CUV105 successfully advancing, M lines being anticipated and cash stockpiling...the company is painted black by all on lookers. JPM controls the share price like a video game, justifying the doomsday predictions.
30 years of investing, I've never seen anything like Clinuvel. I am certain it will pay off in the quickly approaching "end." SCRIPT!!!
CUV Price at posting:
$9.69 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)